Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

LGVN

Longeveron (LGVN)

Longeveron Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LGVN
DateTimeSourceHeadlineSymbolCompany
12/13/202112:55PMEdgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:LGVNLongeveron Inc
12/07/20214:52PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LGVNLongeveron Inc
12/06/20218:05AMInvestorsHub NewsWireLongeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)NASDAQ:LGVNLongeveron Inc
12/06/20218:00AMGlobeNewswire Inc.Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)NASDAQ:LGVNLongeveron Inc
12/03/20214:30PMGlobeNewswire Inc.Longeveron Inc. Announces Closing of a $20.5 Million Private PlacementNASDAQ:LGVNLongeveron Inc
12/01/20213:16AMGlobeNewswire Inc.Longeveron Inc. Announces Pricing of a $20.5 Million Private PlacementNASDAQ:LGVNLongeveron Inc
11/30/20213:20PMGlobeNewswire Inc.Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty PatientsNASDAQ:LGVNLongeveron Inc
11/18/20214:59PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LGVNLongeveron Inc
11/18/20218:03AMInvestorsHub NewsWireU.S. Food and Drug Administration Approves Longeveron's Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart ConditionNASDAQ:LGVNLongeveron Inc
11/18/20218:00AMGlobeNewswire Inc.U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart ConditionNASDAQ:LGVNLongeveron Inc
11/12/20214:04PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LGVNLongeveron Inc
11/12/20218:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LGVNLongeveron Inc
11/12/20218:00AMGlobeNewswire Inc.Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial ResultsNASDAQ:LGVNLongeveron Inc
11/08/20218:30AMGlobeNewswire Inc.Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021NASDAQ:LGVNLongeveron Inc
11/05/20218:30AMGlobeNewswire Inc.Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease TrialNASDAQ:LGVNLongeveron Inc
10/20/20218:30AMGlobeNewswire Inc.Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)NASDAQ:LGVNLongeveron Inc
10/14/20219:01AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGVNLongeveron Inc
10/14/20219:00AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGVNLongeveron Inc
10/14/20218:00AMGlobeNewswire Inc.Longeveron to Present at the 2021 Dawson James Securities 6th Annual Small Cap Growth ConferenceNASDAQ:LGVNLongeveron Inc
10/13/20216:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGVNLongeveron Inc
10/12/20219:31AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGVNLongeveron Inc
10/12/20219:30AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGVNLongeveron Inc
10/12/20219:30AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGVNLongeveron Inc
09/29/202110:00AMGlobeNewswire Inc.Longeveron Announces Potential Biomarker Correlating with Lomecel-B BioactivityNASDAQ:LGVNLongeveron Inc
09/29/20219:32AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LGVNLongeveron Inc
09/28/20218:00AMGlobeNewswire Inc.Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia ResearchNASDAQ:LGVNLongeveron Inc
09/21/20218:00AMGlobeNewswire Inc.Longeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia ResearchNASDAQ:LGVNLongeveron Inc
09/13/20219:19AMGlobeNewswire Inc.Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell TherapyNASDAQ:LGVNLongeveron Inc
09/09/20219:29AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LGVNLongeveron Inc
09/09/20218:00AMGlobeNewswire Inc.Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome PatientsNASDAQ:LGVNLongeveron Inc
 Showing the most relevant articles for your search:NASDAQ:LGVN

Your Recent History

Delayed Upgrade Clock